Abiopharma

🔍 Turner Christopher Durant (Executive)

Company: Nuvalent, Inc. (NUVL)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Sold 871 shares of Class A Common Stock at $96.06 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 61,676.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,119 shares of Class A Common Stock at $96.85 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 60,557.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 1,929 shares of Class A Common Stock at $97.96 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 58,628.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 317 shares of Class A Common Stock at $98.52 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 58,311.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 1,321 shares of Class A Common Stock at $96.75 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 56,990.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 1,635 shares of Class A Common Stock at $97.33 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 55,355.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 225 shares of Class A Common Stock at $98.4 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 55,130.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Acquired 17,500 shares of Class A Common Stock (Direct)
  Date: 2026-01-07 | Code: A | equity_swap_involved: false | shares_owned_after: 72,630.00 | transaction_form_type: 4 | Footnotes: F9
• Acquired 17,500 shares of Stock Option (Right to Buy) at $106.82 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2036-01-07 | equity_swap_involved: false | shares_owned_after: 17,500.00 | transaction_form_type: 4 | Footnotes: F10

Footnotes:

• F1: The sale was effected pursuant to a durable Rule 10b5-1 sell-to-cover instruction letter entered into on December 6, 2023 to satisfy the reporting person's tax withholding obligations upon the vesting of previously granted equity awards.
• F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.34 to $96.33, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) of this Form 4.
• F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.34 to $97.33, inclusive.
• F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.34 to $98.33, inclusive.
• F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.34 to $99.10, inclusive.
• F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.03 to $97.02, inclusive.
• F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.03 to $98.02, inclusive.
• F8: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.04 to $98.74, inclusive.
• F9: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in three equal annual installments following January 7, 2026, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
• F10: The shares underlying this option vest over the four years following January 7, 2026 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.